ClinicalTrials.gg
CompletedNCT00925743Updated May 16, 2013

A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

A Phase 1 interventional study of cabazitaxel (XRP6258) in Solid Cancer, sponsored by Sanofi. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-16.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed as a phase 1, multicenter, open-label, single arm, dose-escalation, study of Cabazitaxel in combination with cisplatin, to determine safety, pharmacokinetics (PK), and efficacy in solid tumors (parts 1 and 2) and single sequence, two-treatment, crossover studies to determine the effect of strong CYP3A4 inhibition and induction on the PK of Cabazitaxel in patients with solid tumors (part 3 and part 4, respectively).

There are 4 parts to the study:

Part 1: Determine the Dose Limiting Toxicities (DLT)'s and Maximum Tolerated Dose (MTD) based on safety.

Part 2: Determine the anti-tumor activity of the combination regimen at the Maximum Tolerated Dose (MTD) in an extended cohort of patients.

Part 3: Determine the effect of a strong CYP3A4 inhibitor (ketoconazole) on the pharmacokinetic (PK) of Cabazitaxel.

Part 4: Determine the effect of a strong CYP3A4 inducer (rifampin) on the pharmacokinetic (PK) of Cabazitaxel.

Read the detailed description

The total duration on the study per subject will be about 26 weeks broken down as follows:

  • A maximum of 21-day screening phase,
  • 21-days (+/- 2 weeks) study treatment cycles,
  • 30-day follow-up visit after the last dose of study medication.
  • Cut-off date for parts 1, 2, 3 and 4: when the last patient has completed 6 cycles (parts 1 and 2) or 2 cycles (parts 3 and 4) of treatment or discontinued study treatment (for disease progression, unacceptable toxicity, withdrawal of consent, or investigator's decision to withdraw), whichever comes first, in the corresponding part.

Patients still receiving treatment at the cut-off date may continue to receive treatment beyond the cut-off date at investigator's discretion if benefiting.

02

Conditions studied

  • Solid Cancer

Keywords

  • Phase 1
  • XRP6258
  • cisplatin
  • Antineoplastic Combined Chemotherapy Protocols
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed or unremovable advanced solid that is metastatic or unresectable, and for which standard curative measures do not exist, but for which cisplatin based therapy is appropriate
  • signed

Exclusion criteria

Exclusion criteria

  • limited physical functioning (as evaluated by the (ECOG) scale)
  • inability to follow study requirements and schedule
  • treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other cancer therapy
  • serious medical illness at same time of study and/or significantly abnormal lab reports
  • lack of pregnancy (women of ), pregnancy, or breast feeding.
  • Women of childbearing potential not protected by highly effective contraceptive method of birth control OTHER than hormonal contraception (Part 4 only).
  • prior significant hearing or kidney problems
  • continued toxic effects of prior chemotherapy
  • cancers that cannot be physically measured (Part 2 only)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    1

    * 5, 15, 20 or 25 mg/m2 * one injection of cabazitaxel on day 1 of each cycle (3 weeks)

    Drug: cabazitaxel (XRP6258)

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicities (DLT)'s of the combination of cabazitaxel and cisplatin (part 1)

    Time frame: first cycle (i.e.3 weeks)

  2. Objective response ratio (Complete response (CR) and partial response (PR)) (part 2)

    Time frame: up to 6 cycles, ie 18 weeks

  3. Pharmacokinetics (PK) of cabazitaxel (part 3 and 4)

    Time frame: up to 6 cycles, ie 18 weeks

Secondary outcomes

  1. Time to progression (TTP) (part 1 and 2)

    Time frame: up to 6 cycles, ie 18 weeks

  2. Duration of response (DR) (Part 1 and 2)

    Time frame: up to 6 cycles, ie 18 weeks

  3. Cabazitaxel pharmacokinetic (part 1 and 2)

    Time frame: up to 6 cycles, ie 18 weeks

07

Study locations

7 sites
  • Investigational Site Number 840008
    Los Angeles, California 90048, United States
  • Investigational Site Number 840003
    San Diego, California 92123, United States
  • Investigational Site Number 840010
    Decatur, Illinois 62526, United States
  • Investigational Site Number 840002
    Baltimore, Maryland 21201, United States
  • Investigational Site Number 840006
    St Louis, Missouri 63110, United States
  • Investigational Site Number 840007
    Cincinnati, Ohio 45267-0542, United States
  • Investigational Site Number 840005
    San Antonio, Texas 78229, United States
08

References and documents

Publications

  • Lockhart AC, Sundaram S, Sarantopoulos J, Mita MM, Wang-Gillam A, Moseley JL, Barber SL, Lane AR, Wack C, Kassalow L, Dedieu JF, Mita AC. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors. Invest New Drugs. 2014 Dec;32(6):1236-45. doi: 10.1007/s10637-014-0145-y. Epub 2014 Aug 13. PubMed 25117475 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2009
First posted
Jun 22, 2009
Start
Jun 2009
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Last update
May 16, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00925743
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jun 22, 2009
Start date
Jun 2009
Primary completion
Mar 2013
Completion
Mar 2013
Last update
May 16, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion